New York City, NY -- (SBWIRE) -- 03/15/2017 -- The Lysosomal acid lipase deficiency (LAAL) Treatment Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The currently available treatment for lysosomal acid lipase deficiency is intended to lower the cholesterol and triglycerides level with help of statins and cholestyramine. Maintaining levels of cholesterol and triglycerides prevents premature atherosclerosis. The lysosomal acid lipase deficiency treatment market is expected to drive the market mainly due to the growing prevalence and lack of approved treatment for it, except for recently approved drug sebelipase alfa. This recent approval of sebelipase alfa drug is also expected to drive the market for lysosomal acid lipase deficiency treatment market. Challenges in lysosomal acid lipase deficiency treatment market is that unawareness of the people about LAAL deficiency. The lysosomal acid lipase deficiency treatment market is also restrained by lack of thorough understanding about the disease as well as treatment.

Global lysosomal acid lipase deficiency treatment market is segmented on basis of treatment type into enzyme replacement therapy, kidney transplantation and stem cell transplantation. FDA approval of drug sebelipase alfa on 8th December 2015 is considered to be a breakthrough in lysosomal acid lipase deficiency treatment market and thus enzyme replacement therapy segment is expected to boost the lysosomal acid lipase deficiency treatment market. While based on disease indication lysosomal acid lipase deficiency treatment market is segmented into wolman disease and cholesterol ester storage disease Cholesterol ester storage disease segment is expected to have a greater share due to high demand in this segment.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14569

On basis of region or country the lysosomal acid lipase deficiency treatment market is segmented into North America (NA), Latin America (LA), Europe, Asia Pacific (APAC), Middle East and Africa (MEA). In terms of region, due to high prevalence of lysosomal acid lipase deficiency disease, Europe and North America are expected to boost lysosomal acid lipase deficiency treatment market. The major key players in the lysosomal acid lipase deficiency treatment market are, AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc., Alexion Pharmaceutical Inc., Lonza Group Ltd., Thermo Fisher Scientific, Teva Pharmaceutical Industries Ltd.

To View TOC of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/toc/14569